London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings

blonca9
Nov 20, 2024
1 min read

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight